	US 12,128,091 B2
	Pet food formulation with cannabinoids
Anja Skodda, Venice, CA (US)
Assigned to PAW POWER, INC., Venice, CA (US)
Filed by PAW POWER, INC., Venice, CA (US)
Filed on Oct. 20, 2021, as Appl. No. 17/505,689.
Application 17/505,689 is a division of application No. 16/560,565, filed on Sep. 4, 2019, granted, now 11,191,814.
Claims priority of provisional application 62/726,467, filed on Sep. 4, 2018.
Prior Publication US 2022/0040269 A1, Feb. 10, 2022
Int. Cl. A61K 38/39 (2006.01); A23K 20/111 (2016.01); A23K 20/121 (2016.01); A23K 20/147 (2016.01); A23K 20/163 (2016.01); A23K 20/174 (2016.01); A23K 50/40 (2016.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61K 31/593 (2006.01); A61K 31/7008 (2006.01); A61K 31/728 (2006.01)

CPC A61K 38/39 (2013.01) [A23K 20/111 (2016.05); A23K 20/121 (2016.05); A23K 20/147 (2016.05); A23K 20/163 (2016.05); A23K 20/174 (2016.05); A23K 50/40 (2016.05); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/593 (2013.01); A61K 31/7008 (2013.01); A61K 31/728 (2013.01)]

20 Claims

1. A method for reducing a symptom of degenerative joint disease in a non-human animal, the method comprising:

administering a food supplement to the non-human animal in need thereof, the food supplement consisting of:

an extracellular matrix component,

a vitamin or vitamins, and

a cannabinoid or cannabinoids, wherein the food supplement is effective at reducing at least one symptom of the degenerative joint disease and wherein an effective amount of the extracellular matrix component is 90-99% by weight of the food supplement.